Biosketch

Guillaume Canaud is a prominent figure in the Renal Division of Necker Enfants Malades Hospital. He completed his nephrology training from 2002 to 2012 and dedicated four years (2008 to 2012) to earn his PhD in Dr. Terzi's laboratory. Subsequently, he joined the Bonventre Lab in Boston, USA, from 2012 to 2014 for a postdoctoral stint before returning to INEM, where he established his own research group specializing in translational medicine focusing on rare disorders associated with the RAS/PIK3CA/AKT/mTOR pathways.

Notably, he has secured over €20 million in grants since 2015, including an ERC grant (2015), an ERC Proof of Concept Grant (2016), and an ERC Consolidator (2020).

With his research group, Pr. Canaud has identified a promising therapeutic approach for individuals with a rare genetic disorder known as PIK3CA-Related Overgrowth Syndrome (PROS). He has been instrumental in advancing the clinical development of this treatment for PROS patients, leading to the launch of three clinical trials since 2019. These efforts culminated in the accelerated approval of alpelisib by the US FDA on April 6, 2022, for PROS patients over 2 years old. Guillaume Canaud's exceptional contributions have also earned him several national and international accolades.